Arax Advisory Partners
PPBT icon

Arax Advisory Partners’s Purple Biotech PPBT Stock Holding History

Arax Advisory Partners’s Portfolio PPBT Stock Details PPBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-1,453
Closed -$2.44K – 5454
2026
Q2 		$2.44K Buy
+1,453
New +$4.9K ﹤0.01% 4777

Other funds holding PPBT

SmartHarvest Portfolios
SmartHarvest Portfolios Poulsbo, Washington $258M AUM 39.79% 1-Year Est. Return
HRT Financial
HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $192B AUM 13.66% 1-Year Est. Return
IFG Advisory
IFG Advisory Atlanta, Georgia $3.01B AUM 18.54% 1-Year Est. Return

Arax Advisory Partners's PPBT Position: Q3 2026 in Review

Arax Advisory Partners sold out of Purple Biotech (PPBT) in Q3 2026, closing a stake of 1,453 shares — an estimated $2.44K sold.

Arax Advisory Partners first reported a position in PPBT in Q2 2026 and held it in 1 quarter. The position peaked at $2.44K in Q2 2026. 11 funds tracked by Wall St. Rank hold PPBT as of Q3 2026.

  • Arax Advisory Partners reported no remaining Purple Biotech position as of Q3 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 1,453 Purple Biotech shares in Q3 2026, an estimated $2.44K.
  • Arax Advisory Partners first reported a position in Purple Biotech in Q2 2026 and held it in 1 quarter.
  • Arax Advisory Partners's Purple Biotech position peaked at $2.44K in Q2 2026.
  • 11 funds tracked by Wall St. Rank held Purple Biotech as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.